Children as young as six will be part of a new COVID-19 vaccine trial, the University of Oxford announced Saturday. “Building on previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in all adults, this trial will assess if children and young adults aged 6–17 years make a good immune response with the ChAdOx1 nCoV-19 vaccine,” the university said in a statement. ChAdOx1 was developed by the university and AstraZeneca in a bid to prevent transmission of the CCP (Chinese Communist Party) virus, which causes COVID-19. COVID-19 is a disease that began appearing in late 2019 in China. The new trial will be single-blind, randomized, and phase II. It will enroll 300 volunteers, of whom up to 240 will get the vaccine. The others will be injected with a control meningitis vaccine. Children between the ages of 6 and 17 …
Children as young as six will be part of a new COVID-19 vaccine trial, the University of Oxford announced Saturday. “Building on previous trials of the vaccine, which have shown that it is safe, produces strong immune system responses and has high efficacy in all adults, this trial will assess if children and young adults
Read More